Vitrolife AB
STO:VITR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
154.0165
265.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VITR stock under the Base Case scenario is 140.28 SEK. Compared to the current market price of 237.6 SEK, Vitrolife AB is Overvalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vitrolife AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VITR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vitrolife AB
Balance Sheet Decomposition
Vitrolife AB
Current Assets | 2.1B |
Cash & Short-Term Investments | 925m |
Receivables | 708m |
Other Current Assets | 477m |
Non-Current Assets | 14.8B |
Long-Term Investments | 54m |
PP&E | 391m |
Intangibles | 14.2B |
Other Non-Current Assets | 154m |
Current Liabilities | 724m |
Accounts Payable | 190m |
Accrued Liabilities | 190m |
Other Current Liabilities | 344m |
Non-Current Liabilities | 3B |
Long-Term Debt | 1.9B |
Other Non-Current Liabilities | 1.1B |
Earnings Waterfall
Vitrolife AB
Revenue
|
3.6B
SEK
|
Cost of Revenue
|
-1.5B
SEK
|
Gross Profit
|
2.1B
SEK
|
Operating Expenses
|
-5.6B
SEK
|
Operating Income
|
-3.6B
SEK
|
Other Expenses
|
-249m
SEK
|
Net Income
|
-3.8B
SEK
|
Free Cash Flow Analysis
Vitrolife AB
SEK | |
Free Cash Flow | SEK |
VITR Profitability Score
Profitability Due Diligence
Vitrolife AB's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Vitrolife AB's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
VITR Solvency Score
Solvency Due Diligence
Vitrolife AB's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Vitrolife AB's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VITR Price Targets Summary
Vitrolife AB
According to Wall Street analysts, the average 1-year price target for VITR is 274.13 SEK with a low forecast of 252.5 SEK and a high forecast of 299.25 SEK.
Dividends
Current shareholder yield for VITR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VITR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Contact
IPO
Employees
Officers
The intrinsic value of one VITR stock under the Base Case scenario is 140.28 SEK.
Compared to the current market price of 237.6 SEK, Vitrolife AB is Overvalued by 41%.